Pacira BioSciences, Inc. (PCRX) — Analyst outlook / Analyst consensus target is. Based on 36 analyst ratings, the consensus is bullish — 15 Buy, 17 Hold, 4 Sell.
The consensus price target is $27.00, representing an upside of 13.7% from the current price $23.75.
Analysts estimate Earnings Per Share (EPS) of $3.15 and revenue of $0.70B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.15 vs est $3.15 (missed -168.3%). 2025: actual $0.16 vs est $2.95 (missed -94.6%). Analyst accuracy: 0%.
PCRX Stock — 12-Month Price Forecast
$27.00
▲ +13.68% Upside
Average Price Target
Based on 36 Wall Street analysts offering 12-month price targets for Pacira BioSciences, Inc., the price target is $27.00.
The average price target represents a +13.68% change from the last price of $23.75.
PCRX Analyst Ratings
Hold
Based on 36 analysts giving stock ratings to Pacira BioSciences, Inc. in the past 3 months
EPS Estimates — PCRX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.15
vs Est $3.15
▼ 246.5% off
2025
Actual $0.16
vs Est $2.95
▼ 1,746.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — PCRX
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.701B
vs Est $0.699B
▲ 0.3% off
2025
Actual $0.726B
vs Est $0.730B
▼ 0.5% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
